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Natural Killer (NK) Cell 
Alloreactivities against Leukemic 
Cells: Functions beyond Defense
Suwit Chaisri and Chanvit Leelayuwat
Abstract
Immunotherapy using adoptive transfer of natural killer (NK) cells has progres-
sively been utilized in hematologic malignancies over the past decade. Presently, NK 
cell immunotherapy has been promising and feasible in acute leukemia, particularly 
in acute myeloblastic leukemia (AML). Alloreactive NK cells have been exploited 
under the killer immunoglobulin-like receptor (KIR)-ligand mismatches between 
donors and recipients in haploidentical hematopoietic stem cell transplantation 
(haplo-HSCT) after immunosuppressive chemotherapy. Of interest, alloreactive 
NK cells killed residual leukemic cells, dendritic cells (DCs) and T cells in acute leu-
kemia patients and led to significantly improved clinical outcomes. Consequently, 
this chapter provides the KIR genetics and the mechanisms of alloreactive NK cells 
that are shown to be crucial in the successful therapy of acute leukemia (myeloid 
and lymphoid). Altogether, the donor selection algorithm of haplo-HSCT is 
discussed to emphasize the importance and give priority to increase the chances 
of therapy success. These will be useful for students and researchers who work 
in immunogenetics. Furthermore, the knowledge would be applicable to clinical 
research and medical sciences.
Keywords: NK cell alloreactivity, KIR polymorphisms, KIR-ligands mismatch,  
acute leukemia, haploidentical HSCT
1. Introduction
Natural killer (NK) cells play a critical role in innate immune responses against 
infected cells and transformed cells. In the past decades, the molecular mechanisms 
of NK cell killings have been extensively elucidated as well as employed in clini-
cal applications [1, 2]. The effector functions of NK cells are being investigated 
in several pathological conditions, particularly in cancers [3, 4]. Many researches 
highlight on the role of NK cells in hematologic malignancies, particularly in acute 
leukemia. Acute leukemia is a type of cancer in which the bone marrow produces 
too many immature white blood cells and they cannot carry out normal functions. 
In addition, leukemic cells crowd out all blood cell productions in the bone mar-
row, affecting normal blood functions and leading to serious health problems. The 
treatment options for acute leukemia include chemotherapy, radiotherapy and bone 
marrow (hematopoietic stem cell) transplantation. Considering HLA matching 
between donors and patients for hematopoietic stem cell transplantation (HSCT), 
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the patient’s outcomes are related with a closely matched donor, however, not all 
patients are able to find a suitable donor. To overcome the limitations of donor 
availability, a partially matched or haploidentical HSCT (haplo-HSCT) has been 
established as an alternative expedient and being a mode of curative therapy for 
hematologic malignancies [5], particularly in acute leukemia patients [6]. In addi-
tion, a complication of allogeneic HSCT has improved with graft versus host disease 
(GvHD) prophylaxis to prevent the effects of donor T cells. Evidently, the role of 
NK cell alloreactivity can significantly improve clinical outcomes in acute leukemia 
patients [7]. Among NK cell receptors, killer immunoglobulin-like receptor (KIR) 
has increasingly been exploited in the aspect of immunotherapy for acute leuke-
mia, which mismatches between KIR on donor NK cells and their cognate ligand 
HLA class I on receipts lead to alloreactivity of NK cells in haplo-HSCT setting. 
Alloreactive NK cells exert powerful activity in killing residual leukemic cells, lead-
ing to preventing disease relapse and improving survival [7, 8]. With these reasons, 
NK cell alloreactivities mediated by KIR-ligand mismatches has been increasingly 
utilized in aspect of immunotherapy for clinical applications. Therefore, this 
chapter provides KIR genetics and KIR-mediated NK cell alloreactivities that have 
been shown to be crucial in the successful therapy of acute leukemia (myeloid and 
lymphoid). Additionally, donor selection algorithm of haploidentical HSCT mis-
match is discussed to emphasize its role in increasing success rate of these therapies.
2. Natural killer (NK) cells
NK cells are considered a part of lymphocytes that account for approximately 
10% of blood lymphocytes. NK cells are characterized by expression of CD56 
surface antigen and a lack of CD3 antigen. Based on the density of CD56 expres-
sion, human NK cells are phenotypically divided into two groups: CD56bright and 
CD56dim. Of these NK cell populations, CD56dim NK cells represent up to 90% of 
NK cells in human peripheral blood mononuclear cells (PBMCs) and are considered 
the most cytotoxic subset, while CD 56bright NK cells comprise approximately 10% 
of NK cells in PBMCs and are known as the cytokine-producing subset. NK cells 
play important role of the first line of defense to infected cells and transformed cells 
without prior sensitization [9, 10]. Several receptors present on NK cells are cur-
rently identified, however, they are classified into two groups depended on signal 
transductions derived from those receptors, namely activating and inhibitory receptors 
[11] (Table 1). Importantly, the dynamic equilibrium of signals obtained by these 
receptors is important to determine whether NK cells are activated to kill target cells 
[12, 13]. The missing self-hypothesis has been proposed to explain whether NK cells 
discriminate target cells form healthy “self” cells by their various receptors [14]. 
Normally, engagement of inhibitory receptors by self MHC class I molecule leads 
to transmission of an inhibitory signal to switch off the NK cell functions, while 
down-regulated MHC molecules on target cells by viral infection or malignant 
transformation is recognized and attacked by NK cells. Cytotoxicity and cytokine 
secretion of NK cells depended on the interaction between their receptors and 
their corresponding ligands. Activated NK cells usually exert cytotoxic activity 
through three main pathways. Firstly, the perforin/granzymes pathway, activated 
NK cells release these molecules to intracellular space. The perforin directly forms 
a transmembrane channel on the target cell, leading to increased permeability of 
the target cell membrane and causing osmotic lyses of target cells. In addition, 
granzymes enter the cytoplasm of target cells through transmembrane pores to 
promote target cells apoptosis [15]. Secondly, the Fas/FasL pathway, when Fas on 
NK cells binds to FasL on the target cells, Fas derivers a death signal to the target cell 
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and they undergo apoptosis [16, 17]. Lastly, the cytokine pathway, NK cells secrete 
various cytokines, such as IFN-γ, TNF-α, GM-CSF and IL-10. These cytokines play 
an important role in immune responses of NK cells. For example, TNF-α alters the 
stability of lysosome in target cells, resulting in leakage of various hydrolases, effect 
on metabolism of cell membrane phospholipid and degradation of genomic DNA by 
endonuclease [18]. With these mechanisms, applications of NK cells have currently 
been established in tumor immunotherapy as chimeric antigen receptor-modified 
NK cells (CAR-NK cells) and adoptive immunotherapy.
3.  Killer immunoglobulin-like receptor (KIR) polymorphisms mediated-
heterogeneity of NK cell responses
Killer immunoglobulin-like receptors (KIRs) are cell surface receptors expressed 
on NK cells and subpopulation of T cells. Similar to HLA class I, KIR ligands, KIRs 
are highly polymorphic genes, including allelic polymorphisms, genes content and 
copy number variations [19]. Genetic variations of KIRs and HLA among individuals 
generate heterogeneity of immune responses of NK cells [20]. Interestingly, current 
evidences demonstrate the impact of KIR gene variations on disease susceptibility 
or resistance in several pathological conditions, such as infection, autoimmune/
inflammatory disorder, implantation and particularly in hematopoietic stem cell 
Type of receptors Ligands
Activating receptors
CD94-NKG2C/E HLA-E
NKG2D MIC-A/-B, ULBP1–6
KIR-S HLA-C
NKp30 B7H6, BAT3
NKp44 Proteoglycans
NKp46 Heparin
CD16 IgG
Inhibitory receptors
KIR-L HLA-A, -B, -C
LAIR-1 Collagen
LILRB1 HLA-A, -B, -C
NKR LLT-1
KLRG1 Cadherins
SIGLEC3, 7,9 Sialic acid
CD94-NKG2A HLA-E
Activating or inhibitory receptors
KIR2DL4 HLA-G?
KIR-S: killer cell immunoglobulin-like receptor with short cytoplasmic tail; KIR-L: killer cell immunoglobulin-
like receptor with long cytoplasmic tail; LAIR-1: leukocyte-associated immunoglobulin-like receptor 1; LILRB1: 
leukocyte immunoglobulin-like receptor B1; KLR: killer cell lectin-like receptor; NKR: NK cell receptor; SIGLEC: 
sialic acid-binding immunoglobulin-type lectins; HLA: human leukocyte antigen; LLT: lectin-like transcript 1. 
IgG: immunoglobulin G; BAT3: leukocyte antigen-B-associated transcript 3; MIC: MHC class I-related chain 
family; ULBP: UL16-binding proteins; HLA-G?: It is controversial whether HLA-G is a lignad of KIR2DL4.
Table 1. 
NK cell receptors and their cognate ligands.
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transplantation [21]. Here, to better understand the role of NK cell alloreactivities, 
we thoroughly describe the basis of KIRs as well as its role in the immune system.
3.1 Killer immunoglobulin-like receptors (KIRs, CD158)
Killer immunoglobulin-like receptors are type I transmembrane glycoprotein 
expressed on the plasma membrane of NK cells, subpopulations of memory T cells 
and most of CD8+ T cells [22, 23]. The KIR family consists of 15 functional genes 
(KIR2DL1–4, 2DL5A, 2DL5B, 2DS1–5, 3DL1–3, 3DS1) and 2 pseudogenes (2DP1 and 
3DP1) encoded within a 150 kb region of the leukocyte receptor complex (LRC) 
located on chromosome 19 (19q13.4) [24, 25] . The KIR proteins have either two or 
three extracellular immunoglobulin domains (KIR2D or KIR3D) and cytoplasmic 
(CYT) tails with long (L) or short (S) tails. Based on structural feature, a long cyto-
plasmic tail (KIR2DL or KIR3DL) contains immunoreceptor tyrosine-based inhibi-
tory motif (ITIM) that functions to inhibit NK cell responses [26]. In contrast, a 
short cytoplasmic tail (KIR2DS or KIR3DS) has a positive charge amino acid residue 
in the transmembrane region to associate with DAP12 containing an immunorecep-
tor tyrosine-based activating motif (ITAM) that turns on NK cell functions [27]. 
Uniquely, KIR2DL4, a long cytoplasmic tail containing ITIM and linking with an 
adaptor molecule FcεRI, can deliver both activating and inhibitory signals to control 
NK cell responses [28, 29]. However, the mechanism by which KIR2DL4 delivers 
activating or inhibitory signals to NK cells is not established. Two pseudogenes, 
KIR2DP1 and KIR3DP1, are not expressed on NK cells.
3.2 Diversity of KIRs
The extensive variation of KIR loci is achieved through allelic polymorphisms, a 
combination of gene content (absence/presence polymorphisms) and copy number 
variations. Firstly, allelic polymorphisms of KIR have been documented in the 
Immuno Polymorphism Database (IPD) showing each KIR locus contains 16–164 
alleles of different genes [30]. Later, a combination of genes content generates 
distinct KIR genotypes, showing 625 different KIR genotypes reported in 171 popu-
lations worldwide [31]. Lastly, copy number variation (CNV) of KIR is currently 
studied and demonstrated that equal and unequal crossing over generates indi-
vidual KIR gene duplication, deletion and hybridization [32]. Moreover, stochastic 
and variegated KIR expressions on NK cells by epigenetic regulation facilitate 
a diverse repertoire of NK cell clones within an individual [33] (Figure 1). As a 
consequence, the influence of KIR diversity on immune responses has been reported 
in several diseases [21, 34–36]. On the basis of gene content, KIRs are classified into 
group A and B haplotypes [37]. Both group A and B haplotypes are conserved with 
four framework genes (KIR3DL3-3DP1-2DL4-3DL2). Group A haplotype consists 
of the four framework genes and 2DL3, 2DP1, 2DL1, 3DL1 or 2DS4, whereas group 
B haplotype has variable gene content. Distinctly, group A haplotype shows pre-
dominantly inhibitory KIR genes except KIR2DS4, but group B haplotype contains 
dominantly activating KIR genes. The distributions of KIR haplotypes have been 
studied, showing variations of A and B are found among populations [38–43].
3.3 KIR and their cognate ligands
Both inhibitory and activating KIRs on NK cells recognize HLA class I mol-
ecules of target cells. Most KIR ligands have recently characterized as shown in 
Table 2, whereas some KIR ligands are still unknown [44–47]. The affinity of KIR 
and HLA interaction affects NK cell responses [48]. Remarkably, activating KIRs 
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(KIR2DS1/2) and inhibitory KIRs (KIR2DL1/2) can bind the same HLA molecules. 
However, the affinity of inhibitory KIR-binding HLA is higher than activating KIR-
binding HLA [49, 50]. It is believed that the lower affinity of activating KIR and 
HLA interaction would be evolved to avoid self-aggression.
4.  Alloreactive NK cells from transplantation to adoptive 
immunotherapy
Over the past decade, adoptive transfer allogeneic NK cells have been emerged 
as promising immunotherapy for hematological malignancies [8, 51, 52]. The role 
of alloreactive NK cells is considered to be beneficial in achieving better outcomes 
KIR KIR ligand (HLA) Function
2DL1 HLA-C2 (HLA-CLys80) Inhibition
2DL2 HLA-C1 (HLA-CAns80) Inhibition
2DL3 HLA-C1, HLA-C2 (weak) Inhibition
2DL4 HLA-G?* Activation/inhibition?
2DL5 Unknown Inhibition
2DS1 HLA-C2 (HLA-CLys80) Activation
2DS2 HLA-C1 (HLA-CAns80), β2-Microglobulin Activation
2DS3 Unknown Activation
2DS4 HLA-A11 and some HLA-C alleles Activation
2DS5 Unknown Inhibition
3DL1 HLA-Bw4 Inhibition
3DL2 HLA-A3, -A11 Inhibition
3DL3 Unknown Inhibition
3DS1 HLA-Bw4? Activation
*The ligand for KIR2DL4 is still controversy [44, 45].
Table 2. 
KIR and their ligands (HLA) specificity.
Figure 1. 
NK cell repertoires. Individual KIR genotype generates a diverse repertoire of NK cells by stochastic expression. 
KIR expression on NK cells is influenced by HLA class I and CD94:NKG2A.
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after haploidentical HSCT (haplo-HSCT). Presently, haplo-HSCT is an alternative 
option when completely matched related or unrelated donors are not available. 
Historically, although haplo-HSCT can lead to graft versus host disease (GvHD) 
which has undesirable effect in post HSCT, this problem has been currently solved 
by performing of T cell depletion before graft infusion. After chemotherapy in 
AML patients, T cell prophylaxis has been used together with high stem cell doses, 
resulting in fast NK cell alloreactivities and slow T cell reconstitution. Moreover, 
graft versus leukemic cells mediated by NK cell, alloreactivities have been exploited 
which they can beneficially lead to reduced relapse, and improve survival [53]. 
Based on the interactions between NK cell receptors and their ligands, it was 
believed that allogeneic NK cells do not receive inhibition signals from the recipient 
HLA, leading NK cells to exert powerful anti-leukemia activity [54]. Regarding 
KIR-ligand mismatches between donor and recipient under haplo HSCT setting, 
alloreactive NK cells play crucial roles against leukemic cells, recipients’ DCs and 
T cells [55], resulting in reduced leukemic relapses, GvHD and graft rejection, 
respectively (Figure 2). With these reasons, a number of studies have extensively 
investigated the role of KIR-ligand mismatches in both pre-clinical and clinical 
setting to evaluate the success in leukemia therapy. Additionally, four situations in 
predicting NK cell alloreactivities after haplo-HSCT have been proposed based on 
the deference in definition of KIR mismatches between the donor NK cells and the 
recipient’s HLA [56] (Figure 3).
4.1 KIR-ligand (HLA) mismatch or missing-self-model
The KIR-ligand mismatch model, also called ligand incompatibility, has been 
proposed that an expression of HLA class I molecules (KIR ligand) on donor are 
Figure 2. 
The role of NK cell alloreactivities in acute leukemia. Beneficial effects of NK cell alloreactivities on the 
outcomes of acute leukemia under haplo-HSCT setting, adoptive transfer NK cells mediated activity against 
residual leukemic cells, recipient’s T cells and dendritic cells, resulting in reduced the risk of relapse, graft 
rejection and GvHD, respectively.
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incompatible with recipient’s HLA class I molecules [57, 58]. This model has been 
assumed that donor NK cells have inhibitory KIR that is missing its ligand on recipi-
ent. For example, NK cells from a HLA-C1/C2 donor will be alloreactive against a 
HLA-C2/C2 recipient, where it is assumed that KIR2DL2 is expressed on donor NK 
cells (Figure 3A).
4.2 Receptor-ligand mismatch model
The receptor-ligand mismatch model states that donor NK cells represent 
inhibitory KIR in mismatching with HLA class I on the recipient target cells, 
Figure 3. 
Situations of NK cell alloreactivity in post-HSCT. (A) The KIR-ligand (HLA) mismatch or missing-self-
model; NK cell alloreactivity is mediated by the lack of HLA ligand expression on recipient for inhibitory 
KIR on donor’s NK cell which the presence of KIR expression on donor is assumed. High resolution HLA 
genotyping is performed in donor and recipient. (B) The receptor-ligand model; NK cell alloreactivity is 
mediated by the lack of HLA ligand expression on recipient for inhibitory KIR which the presence of KIR 
expression on donor NK cell is verified by genotyping and flow cytometry. The donor HLA is irrelevant 
to recipient. (C) The missing-ligand model; NK cell alloreactivity is mediated by the lack of at least one 
of HLA ligand (HLA-C1, -C2 or -Bw4) expression on recipient for inhibitory KIR and the donor HLA 
is irrelevant to recipient. (D) The presence of activating KIR model; NK cell alloreactivity is mediated 
by interaction of activating KIR on donor NK cell and HLA ligand on recipient target cell which KIR B 
haplotype contains more activating KIR than A/A haplotype. KIR genotyping was investigated in donor 
and recipient and some studies detected activating KIR on donor cells.
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leading to NK cell alloreactivities in graft versus host direction [59]. This model is 
therefore required for KIR genotyping in donor as well as HLA typing in recipient 
(Figure 3B).
4.3 Missing-ligand model
Notably, the HLA is only genotyped in recipients and missing HLA-C1, C2 
or Bw4 for inhibitory KIR on donor can lead to NK cell alloreactivities [58]. For 
example, recipient represents HLA-C2/C2, therefore, it is assumed (not investi-
gated) that donor NK cells expressing KIR2DL2 to be alloreactive due to missing 
HLA-C1 ligand (Figure 3C).
4.4 Presence of activating KIR model
Here, in this model, activating KIR on donor cells is measured to predict NK 
cell alloreactivities because the interactions between donor activating KIRs and 
their ligands on recipient can lead to NK cells achieving activation signals [60] 
(Figure 3D).
5. The role of NK cell alloreactivities in post HSCT
Several studies have revealed an influence of alloreactive NK cells in acute 
leukemia patients, where alloreactive NK cells deliver promising better outcomes in 
term of anti-leukemia activity. Predominantly, KIR-mediated NK alloreactivity has 
been demonstrated to be the most clinically significant relevance to AML, while its 
role in ALL remains unclear.
5.1 Acute myeloblastic leukemia (AML)
As acute myeloblastic leukemia was more susceptible to NK cell cytotoxicity 
than solid tumors [61], the role of adoptive transfer NK cells against leukemia 
was investigated in AML patients [62]. Anti-leukemic effect of allogeneic NK 
cells has been extensively studied under haplo-HSCT with the mismatches of 
KIR and cognate ligands between donor and recipient. Interestingly, Ruggeri 
and coworkers initially reported allogeneic NK cells mediated cytotoxicity 
against recipients’ leukemic cells [53]. Later, the impact of NK cells allore-
activity in preventing AML relapse, GVHD and rejection was confirmed in 
clinical setting and mouse model [63]. Taken together, this condition has been 
explored under T cell depleted to avoid graft versus host effect and high doses 
of infused stem cell transplantation [54, 63, 64]. Remarkably, this approach was 
investigated in 21 AML children who received haplo-HSCT, showing donor-
derived alloreactive NK cells killed leukemic cells in KIR-ligand mismatches, 
even late after transplantation [7]. Altogether, the doses of infused NK cell and 
immunosuppression were evaluated in children with AML to consider safety 
and effectiveness of alloreactive NK cells therapy [65]. Moreover, successfully 
transferred NK cells immunotherapy were reported in elderly AML who were 
not candidates for HSCT, demonstrating this approach was feasible and safe in 
elderly patients [8, 66].
Haplo-HSCT with KIR-ligand mismatches has been a promising strategy in 
AML for adoptive transfer of NK cells for immunotherapy [67, 68]. The incom-
patibility of three main inhibitory KIR loci (2DL1, 2DL2/3 and 3DL1) with their 
ligands (HLA-C2, HLA-C1 and HLA-Bw4) has been extensively investigated, and 
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found to be relevant for better clinical outcomes [69, 70]. To explain the potential 
benefits of alloreactive NK cells against leukemia based on an absence of inhibi-
tory signal delivered by KIR on donor’s NK cells, it has been shown that KIR2DL1+ 
NK cells lyse leukemia in HLA-C1/C1 recipients, whereas KIR2DL2/3+ NK cells 
partially lyse leukemia in HLA-C2/C2 recipients due to low-affinity binding, and 
that KIR3DL1 + NK cells lyse HLA-Bw4− leukemia of recipients, where HLA-Bw4− 
would be HLA-A or HLA-B as determined by the serotypic specificity. However, 
for the activating KIR model, KIR2DS1+NK cells have demonstrated a potent 
reactivity against HLA-C2 expressing allogeneic target cells in vitro [60, 71], 
particularly on T cells and dendritic cells. As mentioned, although NK cell-based 
immunotherapy has been a promising approach in adult and childhood [8, 65, 
66], there are additional issues that need to be considered in achieving a success-
ful therapy. Firstly, the minimum or optimal number of infused NK cells is really 
required to achieve therapeutic effect that remains inconclusive due to lack of 
standardized technical procedure for qualifying alloreactive NK cells [67, 68].  
Additionally, it became clear that infused NK cells favor IL-2 and IL-15 for expan-
sion and survival [51, 72], however, administration of IL-15 after infusion has 
been recommended because IL-2 can promote host regulatory T cells to inhibit 
allogeneic NK cells.
Given the crucial role of alloreactive NK cells in graft versus leukemia (GVL) 
effect in haplo-HSCT, the predictive algorithm for donor selection is being devel-
oped in AML treatment. Several research groups have explored feasibility of NK 
cell-based immunotherapy, including in vivo and in vitro studies as well as clinical 
trials. Predominantly, mismatches of donors’ inhibitory KIR expressing NK cells 
(2DL1, KIR2DL2/3 and KIR3DL1) with HLA class I of the patients have been 
well-documented that were relevant to therapeutic effect of NK immunotherapy 
in AML [7, 66, 73]. For activating KIRs, only KIR2DS1 has been reported to associ-
ate with NK cell alloreactivities against target cells expressing HLA-C2 [60, 74]. 
Moreover, KIR haplotypes and clinical outcomes have been observed, showing 
donors with group B KIR haplotype have improved relapse—free survival for 
AML patients under unrelated HSCT [75]. With these reasons, KIR-mediated NK 
cell functions in haplo-HSCT should be taken in to account for donor selections, 
since the potential benefit of NK alloreactivity has improved survival and clinical 
outcomes in AML patients. Moreover, phase I and II clinical trials have been being 
studied to evaluate the feasibility and safety [76, 77] for further applications. 
Therefore, haplo-HSCT with T cell depletion, KIR-mediated NK cell alloreactivi-
ties should be considered for donor selections using an algorithm in which KIR-
ligand mismatches could be predicted. This is available as an online calculator 
(https://www.ebi.ac.uk/ipd/kir/ligand.html).
5.2 Acute lymphoblastic leukemia (ALL)
Since the role of alloreactive NK cells in AML were reported, the influence of 
KIR on the outcome of ALL patients in haplo-HSCT setting has been investigated. 
Like AML, the approach based upon KIR-ligand mismatches and the presence 
of donor’s KIR2DS1+ NK cells with HLA-C2 expressing target cells mediated NK 
cell alloreactivities against leukemic blasts has been tested [7]. In addition, ALL 
children transplanted from a KIR haplotype B donor showed significantly reduced 
risk of relapse, particularly in donors with high B content score [78]. However, the 
beneficial effect of NK cell alloreactivity has not been obviously noticeable in ALL 
patients in particular mechanisms of NK cells against ALL tumor cells [63, 79, 80]. 
The clinical studies of beneficial effect of NK cell alloreactivities in acute leukemia 
are summarized in Table 3.
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6. Conclusion
This chapter sheds light on adoptive transfer NK cell immunotherapy in haplo-
HSCT setting after immunosuppressive chemotherapy. KIR-ligand mismatches, 
activating KIR with cognate ligand as well as KIR B haplotype, could contribute 
to the potential benefit of allogeneic NK cells against acute leukemia in improv-
ing relapse-free and survival in AML patients. Additionally, the donor selection 
algorithm based on KIR-ligand mismatches is provided and available. Conflicts 
resulted from studies could be explained by the different definitions of KIR ligand 
mismatches, failure of infused NK cells to expand and persist, extensive genetic 
polymorphisms as well as the stochastic surface expressions of specific KIRs on 
individual NK cells. However, some limitations still need to be elucidated in further 
studies to overcome obstacles and achieve successful NK cell immunotherapy 
and clinical impact. For example, the ligands for KIR2DL5 and KIR2DS3 are still 
Study Disease Model Beneficial effect Ref.
Ruggeri et al. 
(1999)
AML, 
ALL, 
CML
KIR-ligand mismatch Antileukemic effect [53]
Ruggeri et al. 
(2002)
AML, 
ALL
KIR-ligand mismatch Reduced relapse, Reduces graft 
rejection, protected GvHD
[63]
Miller et al. 
(2007)
AML, 
MDS, 
CML
Missing-ligand Reduced relapse [81]
Pende et al. 
(2008)
AML, 
ALL
KIR-ligand mismatch Antileukemic effect [7]
Rubnitz et al. 
(2009)
AML Receptor-ligand mismatch No GvHD [65]
Willemze 
et al. (2009)
AML, 
ALL
KIR-ligand mismatch Reduced relapse [82]
Cooley et al. 
(2009)
AML KIR haplotype, KIR-ligand 
mismatch
Improved survival rate [75]
Cooley et al. 
(2010)
AML, 
ALL
KIR haplotype Reduced relapse [83]
Venstrom 
et al. (2010)
AML, 
MDS, 
CML, 
ALL
KIR haplotype Decreased acute GvHD [84]
Curti et al. 
(2011)
AML KIR-ligand mismatch Antileukemic effect [8]
Venstrom 
et al. (2012)
AML Missing-ligand, receptor-
ligand mismatch, presence 
of activating KIR
KIR2DS1 associated with lower 
relapse, KIR3DS1 associated with 
lower mortality
[74]
Cooley et al. 
(2014)
AML Missing-ligand, KIR 
haplotype
Reduced relapse [85]
Curti et al. 
(2016)
AML KIR-ligand mismatch Reduced relapse [66]
AML: acute myeloid leukemia; ALL, acute lymphoid leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic 
syndromes; GvHD: graft versus host disease.
Table 3. 
Clinical studies of beneficial effects of NK cell alloreactivities in acute leukemia.
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unknown. In addition, the molecular mechanisms of KIR and NK cells need to be 
well-established. Eventually, this chapter provides a promising approach of NK cell-
based immunotherapy that has revolutionized hematologic malignancy treatment, 
particularly AML, however, the feasibility has been challenged by complexity and 
understanding of NK cell biology as well as KIRs.
Acknowledgements
SC was supported by Thailand Research Fund and the Commission on Higher 
Education under the Grant for New Researcher (No. MRG6180172).
Conflict of interest
The authors declare no conflict of interest.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
12
Cancer Immunotherapy and Biological Cancer Treatments
References
[1] Rezvani K, Rouce RH. The 
application of natural killer cell 
immunotherapy for the treatment 
of cancer. Frontiers in Immunology. 
2015;6:578. DOI: 10.3389/
fimmu.2015.00578
[2] Paul S, Lal G. The molecular 
mechanism of natural killer cells 
function and its importance in 
cancer immunotherapy. Frontiers in 
Immunology. 2017;8:1124. DOI: 10.3389/
fimmu.2017.01124
[3] Zhang J, Zheng H, Diao Y. Natural 
killer cells and current applications of 
chimeric antigen receptor-modified 
NK-92 cells in tumor immunotherapy. 
International Journal of Molecular 
Sciences. 2019;20(2):317. DOI: 10.3390/
ijms20020317
[4] Rezvani K, Rouce R, Liu E, Shpall 
E. Engineering natural killer cells for 
cancer immunotherapy. Molecular 
Therapy. 2017;25(8):1769-1781. DOI: 
10.1016/j.ymthe.2017.06.012
[5] Mehta RS, Randolph B, Daher 
M, Rezvani K. NK cell therapy 
for hematologic malignancies. 
International Journal of Hematology. 
2018;107(3):262-270. DOI: 10.1007/
s12185-018-2407-5
[6] Handgretinger R, Lang P, Andre 
MC. Exploitation of natural killer cells 
for the treatment of acute leukemia. 
Blood. 2016;127(26):3341-3349. DOI: 
10.1182/blood-2015-12-629055
[7] Pende D, Marcenaro S, Falco M, 
Martini S, Bernardo ME, Montagna 
D, et al. Anti-leukemia activity 
of alloreactive NK cells in KIR 
ligand-mismatched haploidentical 
HSCT for pediatric patients: 
Evaluation of the functional role of 
activating KIR and redefinition of 
inhibitory KIR specificity. Blood. 
2009;113(13):3119-3129. DOI: 10.1182/
blood-2008-06-164103
[8] Curti A, Ruggeri L, D’Addio A, 
Bontadini A, Dan E, Motta MR, et al. 
Successful transfer of alloreactive 
haploidentical KIR ligand-mismatched 
natural killer cells after infusion in 
elderly high risk acute myeloid leukemia 
patients. Blood. 2011;118(12):3273-3279. 
DOI: 10.1182/blood-2011-01-329508
[9] Cerwenka A, Lanier LL. Natural 
killer cell memory in infection, 
inflammation and cancer. Nature 
Reviews. Immunology. 2016;16(2): 
112-123. DOI: 10.1038/nri.2015.9
[10] Hammer Q , Ruckert T, Romagnani 
C. Natural killer cell specificity for 
viral infections. Nature Immunology. 
2018;19(8):800-808. DOI: 10.1038/
s41590-018-0163-6
[11] Vivier E, Tomasello E, Baratin 
M, Walzer T, Ugolini S. Functions of 
natural killer cells. Nature Immunology. 
2008;9(5):503-510. DOI: 10.1038/ni1582
[12] Vivier E, Nunes JA, Vely F. Natural 
killer cell signaling pathways. Science. 
2004;306(5701):1517-1519. DOI: 
10.1126/science.1103478
[13] Long EO, Kim HS, Liu D, Peterson 
ME, Rajagopalan S. Controlling natural 
killer cell responses: Integration of 
signals for activation and inhibition. 
Annual Review of Immunology. 
2013;31:227-258. DOI: 10.1146/
annurev-immunol-020711-075005
[14] Kim S, Poursine-Laurent J, Truscott 
SM, Lybarger L, Song YJ, Yang L, et al. 
Licensing of natural killer cells by host 
major histocompatibility complex class I 
molecules. Nature. 2005;436(7051): 
709-713. DOI: 10.1038/nature03847
[15] Topham NJ, Hewitt EW. Natural 
killer cell cytotoxicity: How do 
they pull the trigger? Immunology. 
2009;128(1):7-15. DOI: 
10.1111/j.1365-2567.2009.03123.x
13
Natural Killer (NK) Cell Alloreactivities against Leukemic Cells: Functions beyond Defense
DOI: http://dx.doi.org/10.5772/intechopen.86519
[16] Mercer F, Kozhaya L, Unutmaz D.  
Expression and function of TNF and 
IL-1 receptors on human regulatory T 
cells. PLoS One. 2010;5(1):e8639. DOI: 
10.1371/journal.pone.0008639
[17] Wajant H. The Fas signaling 
pathway: More than a paradigm. 
Science. 2002;296(5573):1635-1636. 
DOI: 10.1126/science.1071553
[18] Chiossone L, Dumas PY, Vienne M, 
Vivier E. Natural killer cells and other 
innate lymphoid cells in cancer. Nature 
Reviews. Immunology. 2018;18(11): 
671-688. DOI: 10.1038/
s41577-018-0061-z
[19] Chaisri S, Traherne JA, Jayaraman J, 
Romphruk A, Trowsdale J, Leelayuwat 
C. Novel KIR genotypes and gene copy 
number variations in northeastern 
Thais. Immunology. 2018;153(3): 
380-386. DOI: 10.1111/imm.12847
[20] Yawata M, Yawata N, Draghi 
M, Little AM, Partheniou F, 
Parham P. Roles for HLA and 
KIR polymorphisms in natural 
killer cell repertoire selection and 
modulation of effector function. The 
Journal of Experimental Medicine. 
2006;203(3):633-645. DOI: 10.1084/
jem.20051884
[21] Kulkarni S, Martin MP, Carrington 
M. The Yin and Yang of HLA and 
KIR in human disease. Seminars in 
Immunology. 2008;20(6):343-352. DOI: 
10.1016/j.smim.2008.06.003
[22] Bakker AB, Phillips JH, Figdor 
CG, Lanier LL. Killer cell inhibitory 
receptors for MHC class I molecules 
regulate lysis of melanoma cells 
mediated by NK cells, gamma delta T 
cells, and antigen-specific CTL. Journal 
of Immunology. 1998;160(11):5239-5245. 
Epub 1998/05/30
[23] Mingari MC, Ponte M, Vitale C, 
Bellomo R, Moretta L. Expression of 
HLA class I-specific inhibitory receptors 
in human cytolytic T lymphocytes: 
A regulated mechanism that controls 
T-cell activation and function. Human 
Immunology. 2000;61(1):44-50. 
Epub 2000/02/05. DOI: S0198-
8859(99)00158-5 [pii]
[24] Trowsdale J, Barten R, Haude A, 
Stewart CA, Beck S, Wilson MJ. The 
genomic context of natural killer 
receptor extended gene families. 
Immunological Reviews. 2001;181: 
20-38. Epub 2001/08/22
[25] Wende H, Colonna M, Ziegler A, 
Volz A. Organization of the leukocyte 
receptor cluster (LRC) on human 
chromosome 19q13.4. Mammalian 
Genome. 1999;10(2):154-160. Epub 
1999/01/29
[26] Hsu KC, Chida S, Geraghty 
DE, Dupont B. The killer cell 
immunoglobulin-like receptor 
(KIR) genomic region: Gene-order, 
haplotypes and allelic polymorphism. 
Immunological Reviews. 2002;190: 
40-52. Epub 2002/12/21
[27] Lanier LL, Corliss BC, Wu J, Leong 
C, Phillips JH. Immunoreceptor DAP12 
bearing a tyrosine-based activation 
motif is involved in activating NK cells. 
Nature. 1998;391(6668):703-707. Epub 
1998/03/07. DOI: 10.1038/35642
[28] Rajagopalan S, Moyle MW, Joosten 
I, Long EO. DNA-PKcs controls an 
endosomal signaling pathway for 
a proinflammatory response by 
natural killer cells. Science Signaling. 
2010;3(110):ra14. Epub 2010/02/25. 
DOI: 10.1126/scisignal.2000467
[29] Faure M, Long EO. KIR2DL4 
(CD158d), an NK cell-activating 
receptor with inhibitory 
potential. Journal of Immunology. 
2002;168(12):6208-6214. Epub 
2002/06/11
[30] Robinson J, Halliwell JA,  
McWilliam H, Lopez R, Marsh SG.  
Cancer Immunotherapy and Biological Cancer Treatments
14
IPD—The Immuno Polymorphism 
Database. Nucleic Acids Research. 
2013;41(Database issue):D1234-D1240. 
Epub 2012/11/28. DOI: 10.1093/nar/
gks1140
[31] Gonzalez-Galarza FF, Takeshita LY,  
Santos EJ, Kempson F, Maia MH, da 
Silva AL, et al. Allele frequency net 2015 
update: New features for HLA epitopes, 
KIR and disease and HLA adverse 
drug reaction associations. Nucleic 
Acids Research. 2015;43(Database 
issue):D784-D788. Epub 2014/11/22. 
DOI: 10.1093/nar/gku1166
[32] Pyo CW, Guethlein LA, Vu Q , 
Wang R, Abi-Rached L, Norman PJ, 
et al. Different patterns of evolution in 
the centromeric and telomeric regions 
of group A and B haplotypes of the 
human killer cell Ig-like receptor locus. 
PLoS One. 2010;5(12):e15115. Epub 
2011/01/06. DOI: 10.1371/journal.
pone.0015115
[33] Shilling HG, Young N, Guethlein 
LA, Cheng NW, Gardiner CM, Tyan 
D, et al. Genetic control of human NK 
cell repertoire. Journal of Immunology. 
2002;169(1):239-247
[34] Williams AP, Bateman AR, Khakoo 
SI. Hanging in the balance. KIR 
and their role in disease. Molecular 
Interventions. 2005;5(4):226-240. Epub 
2005/08/27. DOI: 10.1124/mi.5.4.6
[35] Bashirova AA, Martin MP, 
McVicar DW, Carrington M. The 
killer immunoglobulin-like receptor 
gene cluster: Tuning the genome for 
defense. Annual Review of Genomics 
and Human Genetics. 2006;7:277-300. 
Epub 2006/07/11. DOI: 10.1146/annurev.
genom.7.080505.115726
[36] Takeshita LY, Gonzalez-Galarza 
FF, dos Santos EJ, Maia MH, Rahman 
MM, Zain SM, et al. A database for 
curating the associations between 
killer cell immunoglobulin-like 
receptors and diseases in worldwide 
populations. Database: The Journal 
of Biological Databases and Curation. 
2013;2013:bat021. Epub 2013/04/16. 
DOI: 10.1093/database/bat021
[37] Uhrberg M, Valiante NM, Shum 
BP, Shilling HG, Lienert-Weidenbach 
K, Corliss B, et al. Human diversity 
in killer cell inhibitory receptor 
genes. Immunity. 1997;7(6):753-763. 
Epub 1998/01/16. DOI: S1074-
7613(00)80394-5 [pii]
[38] Toneva M, Lepage V, Lafay G, 
Dulphy N, Busson M, Lester S, et al. 
Genomic diversity of natural killer cell 
receptor genes in three populations. 
Tissue Antigens. 2001;57(4):358-362. 
Epub 2001/07/14. DOI: tan570411 [pii]
[39] Norman PJ, Stephens HA, Verity 
DH, Chandanayingyong D, Vaughan 
RW. Distribution of natural killer 
cell immunoglobulin-like receptor 
sequences in three ethnic groups. 
Immunogenetics. 2001;52(3-4):195-205. 
Epub 2001/02/28
[40] Rajalingam R, Du Z, Meenagh 
A, Luo L, Kavitha VJ, Pavithra-
Arulvani R, et al. Distinct diversity 
of KIR genes in three southern Indian 
populations: Comparison with world 
populations revealed a link between 
KIR gene content and pre-historic 
human migrations. Immunogenetics. 
2008;60(5):207-217. Epub 2008/03/29. 
DOI: 10.1007/s00251-008-0286-2
[41] Wu GQ , Zhao YM, Lai XY, Yang KL, 
Zhu FM, Zhang W, et al. Distribution 
of killer-cell immunoglobulin-like 
receptor genes in Eastern mainland 
Chinese Han and Taiwanese Han 
populations. Tissue Antigens. 
2009;74(6):499-507. Epub 2009/09/19. 
DOI: 10.1111/j.1399-0039.2009.01366.x
[42] Rajalingam R, Krausa P, Shilling HG, 
Stein JB, Balamurugan A, McGinnis 
MD, et al. Distinctive KIR and HLA 
diversity in a panel of north Indian 
Hindus. Immunogenetics. 2002;53(12): 
15
Natural Killer (NK) Cell Alloreactivities against Leukemic Cells: Functions beyond Defense
DOI: http://dx.doi.org/10.5772/intechopen.86519
1009-1019. Epub 2002/03/21. DOI: 
10.1007/s00251-001-0425-5
[43] Chaisri S, Kitcharoen K, 
Romphruk AV, Romphruk A, Witt CS, 
Leelayuwat C. Polymorphisms of killer 
immunoglobulin-like receptors (KIRs) 
and HLA ligands in northeastern Thais. 
Immunogenetics. 2013;65(9):645-653.  
Epub 2013/07/03. DOI: 10.1007/
s00251-013-0716-7
[44] Moradi S, Berry R, Pymm P, 
Hitchen C, Beckham SA, Wilce MC, 
et al. The structure of the atypical killer 
cell immunoglobulin-like receptor, 
KIR2DL4. The Journal of Biological 
Chemistry. 2015;290(16):10460-10471. 
DOI: 10.1074/jbc.M114.612291
[45] Le Page ME, Goodridge JP, John E,  
Christiansen FT, Witt CS. Response 
to comment on "killer Ig-like receptor 
2DL4 does not mediate NK cell IFN-
gamma responses to soluble HLA-G 
preparations". Journal of Immunology. 
2014;192(9):4003-4004. DOI: 10.4049/
jimmunol.1400492
[46] Jamil KM, Khakoo SI. KIR/
HLA interactions and pathogen 
immunity. Journal of Biomedicine & 
Biotechnology. 2011;2011:298348. Epub 
2011/06/02. DOI: 10.1155/2011/298348
[47] Thiruchelvam-Kyle L, Hoelsbrekken 
SE, Saether PC, Bjornsen EG, Pende D, 
Fossum S, et al. The activating human 
NK cell receptor KIR2DS2 recognizes 
a beta2-microglobulin-independent 
ligand on cancer cells. Journal of 
Immunology. 2017;198(7):2556-2567. 
DOI: 10.4049/jimmunol.1600930
[48] Purdy AK, Campbell KS. Natural 
killer cells and cancer: Regulation 
by the killer cell Ig-like receptors 
(KIR). Cancer Biology & Therapy. 
2009;8(23):2211-2220. Epub 2009/11/20
[49] Biassoni R, Pessino A, Malaspina 
A, Cantoni C, Bottino C, Sivori S, et al. 
Role of amino acid position 70 in the 
binding affinity of p50.1 and p58.1 
receptors for HLA-Cw4 molecules. 
European Journal of Immunology. 
1997;27(12):3095-3099. Epub 
1998/02/17. DOI: 10.1002/eji.1830271203
[50] Vales-Gomez M, Erskine 
RA, Deacon MP, Strominger JL, 
Reyburn HT. The role of zinc in 
the binding of killer cell Ig-like 
receptors to class I MHC proteins. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2001;98(4):1734-1739. 
Epub 2001/02/15. DOI: 10.1073/
pnas.041618298
[51] Miller JS, Soignier Y, Panoskaltsis-
Mortari A, McNearney SA, Yun GH, 
Fautsch SK, et al. Successful adoptive 
transfer and in vivo expansion of human 
haploidentical NK cells in patients with 
cancer. Blood. 2005;105(8):3051-3057. 
DOI: 10.1182/blood-2004-07-2974
[52] Rodriguez NA, Meier PP, Groer 
MW, Zeller JM, Engstrom JL, Fogg 
L. A pilot study to determine the 
safety and feasibility of oropharyngeal 
administration of own mother’s 
colostrum to extremely low-birth-
weight infants. Advances in Neonatal 
Care. 2010;10(4):206-212. DOI: 10.1097/
ANC.0b013e3181e94133
[53] Ruggeri L, Capanni M, Casucci 
M, Volpi I, Tosti A, Perruccio K, et al. 
Role of natural killer cell alloreactivity 
in HLA-mismatched hematopoietic 
stem cell transplantation. Blood. 
1999;94(1):333-339
[54] Aversa F, Tabilio A, Terenzi 
A, Velardi A, Falzetti F, Giannoni 
C, et al. Successful engraftment 
of T-cell-depleted haploidentical 
“three-loci” incompatible transplants 
in leukemia patients by addition of 
recombinant human granulocyte 
colony-stimulating factor-mobilized 
peripheral blood progenitor cells 
to bone marrow inoculum. Blood. 
1994;84(11):3948-3955
Cancer Immunotherapy and Biological Cancer Treatments
16
[55] Locatelli F, Pende D, Mingari 
MC, Bertaina A, Falco M, Moretta A, 
et al. Cellular and molecular basis of 
haploidentical hematopoietic stem 
cell transplantation in the successful 
treatment of high-risk leukemias: Role 
of alloreactive NK cells. Frontiers in 
Immunology. 2013;4:15. DOI: 10.3389/
fimmu.2013.00015
[56] Heidenreich S, Kroger N. Reduction 
of relapse after unrelated donor 
stem cell transplantation by KIR-
based graft selection. Frontiers in 
Immunology. 2017;8:41. DOI: 10.3389/
fimmu.2017.00041
[57] Ljunggren HG, Karre K. In search 
of the ‘missing self ’: MHC molecules 
and NK cell recognition. Immunology 
Today. 1990;11(7):237-244
[58] Symons HJ, Fuchs EJ. Hematopoietic 
SCT from partially HLA-mismatched 
(HLA-haploidentical) related donors. 
Bone Marrow Transplantation. 
2008;42(6):365-377. DOI: 10.1038/
bmt.2008.215
[59] Ruggeri L, Mancusi A, Capanni 
M, Urbani E, Carotti A, Aloisi T, et al. 
Donor natural killer cell allorecognition 
of missing self in haploidentical 
hematopoietic transplantation for 
acute myeloid leukemia: Challenging 
its predictive value. Blood. 
2007;110(1):433-440. DOI: 10.1182/
blood-2006-07-038687
[60] Chewning JH, Gudme CN, Hsu KC, 
Selvakumar A, Dupont B. KIR2DS1-
positive NK cells mediate alloresponse 
against the C2 HLA-KIR ligand group 
in vitro. Journal of Immunology. 
2007;179(2):854-868
[61] Guillerey C, Huntington ND, 
Smyth MJ. Targeting natural killer 
cells in cancer immunotherapy. Nature 
Immunology. 2016;17(9):1025-1036. 
DOI: 10.1038/ni.3518
[62] Ruggeri L, Parisi S, Urbani E, Curti 
A. Alloreactive natural killer cells for the 
treatment of acute myeloid leukemia: 
From stem cell transplantation to 
adoptive immunotherapy. Frontiers in 
Immunology. 2015;6:479. DOI: 10.3389/
fimmu.2015.00479
[63] Ruggeri L, Capanni M, Urbani E, 
Perruccio K, Shlomchik WD, Tosti A, 
et al. Effectiveness of donor natural 
killer cell alloreactivity in mismatched 
hematopoietic transplants. Science. 
2002;295(5562):2097-2100. DOI: 
10.1126/science.1068440
[64] Koehl U, Sorensen J, Esser R,  
Zimmermann S, Gruttner HP, 
Tonn T, et al. IL-2 activated NK cell 
immunotherapy of three children after 
haploidentical stem cell transplantation. 
Blood Cells, Molecules & Diseases. 
2004;33(3):261-266. DOI: 10.1016/j.
bcmd.2004.08.013
[65] Rubnitz JE, Inaba H, Ribeiro RC, 
Pounds S, Rooney B, Bell T, et al. 
NKAML: A pilot study to determine the 
safety and feasibility of haploidentical 
natural killer cell transplantation in 
childhood acute myeloid leukemia. 
Journal of Clinical Oncology. 
2010;28(6):955-959. DOI: 10.1200/
JCO.2009.24.4590
[66] Curti A, Ruggeri L, Parisi S, 
Bontadini A, Dan E, Motta MR, et al. 
Larger size of donor alloreactive NK 
cell repertoire correlates with better 
response to NK cell immunotherapy 
in elderly acute myeloid leukemia 
patients. Clinical Cancer Research. 
2016;22(8):1914-1921. DOI: 
10.1158/1078-0432.CCR-15-1604
[67] Parisi S, Lecciso M, Ocadlikova D,  
Salvestrini V, Ciciarello M, Forte D, 
et al. The more, the better: "Do the right 
thing" for natural killer immunotherapy 
in acute myeloid leukemia. Frontiers 
in Immunology. 2017;8:1330. DOI: 
10.3389/fimmu.2017.01330
[68] Muntasell A, Lopez-Botet M.  
Natural killer cell-based immunotherapy 
17
Natural Killer (NK) Cell Alloreactivities against Leukemic Cells: Functions beyond Defense
DOI: http://dx.doi.org/10.5772/intechopen.86519
in acute myeloid leukemia: Lessons 
for the future. Clinical Cancer 
Research. 2016;22(8):1831-1833. DOI: 
10.1158/1078-0432.CCR-15-3168
[69] Giebel S, Locatelli F, Lamparelli T, 
Velardi A, Davies S, Frumento G, et al. 
Survival advantage with KIR ligand 
incompatibility in hematopoietic stem 
cell transplantation from unrelated 
donors. Blood. 2003;102(3):814-819. 
DOI: 10.1182/blood-2003-01-0091
[70] Hsu KC, Gooley T, Malkki M, 
Pinto-Agnello C, Dupont B, Bignon 
JD, et al. KIR ligands and prediction 
of relapse after unrelated donor 
hematopoietic cell transplantation for 
hematologic malignancy. Biology of 
Blood and Marrow Transplantation. 
2006;12(8):828-836. DOI: 10.1016/j.
bbmt.2006.04.008
[71] Sivori S, Carlomagno S, Falco M, 
Romeo E, Moretta L, Moretta A. Natural 
killer cells expressing the KIR2DS1-
activating receptor efficiently kill T-cell 
blasts and dendritic cells: Implications 
in haploidentical HSCT. Blood. 
2011;117(16):4284-4292. DOI: 10.1182/
blood-2010-10-316125
[72] Bachanova V, Cooley S, Defor TE, 
Verneris MR, Zhang B, McKenna DH,  
et al. Clearance of acute myeloid 
leukemia by haploidentical natural 
killer cells is improved using IL-2 
diphtheria toxin fusion protein. Blood. 
2014;123(25):3855-3863. DOI: 10.1182/
blood-2013-10-532531
[73] Boudreau JE, Giglio F, Gooley 
TA, Stevenson PA, Le Luduec JB, 
Shaffer BC, et al. KIR3DL1/HL A-B 
subtypes govern acute myelogenous 
leukemia relapse after hematopoietic 
cell transplantation. Journal of Clinical 
Oncology. 2017;35(20):2268-2278. DOI: 
10.1200/JCO.2016.70.7059
[74] Venstrom JM, Pittari G, Gooley TA, 
Chewning JH, Spellman S, Haagenson 
M, et al. HLA-C-dependent prevention 
of leukemia relapse by donor activating 
KIR2DS1. The New England Journal of 
Medicine. 2012;367(9):805-816. DOI: 
10.1056/NEJMoa1200503
[75] Cooley S, Trachtenberg E, 
Bergemann TL, Saeteurn K, Klein 
J, Le CT, et al. Donors with group 
B KIR haplotypes improve relapse-
free survival after unrelated 
hematopoietic cell transplantation for 
acute myelogenous leukemia. Blood. 
2009;113(3):726-732. DOI: 10.1182/
blood-2008-07-171926
[76] Shaffer BC, Le Luduec JB, Forlenza 
C, Jakubowski AA, Perales MA, Young 
JW, et al. Phase II study of haploidentical 
natural killer cell infusion for treatment 
of relapsed or persistent myeloid 
malignancies following allogeneic 
hematopoietic cell transplantation. 
Biology of Blood and Marrow 
Transplantation. 2016;22(4):705-709. 
DOI: 10.1016/j.bbmt.2015.12.028
[77] Lee DA, Denman CJ, Rondon 
G, Woodworth G, Chen J, Fisher T, 
et al. Haploidentical natural killer 
cells infused before allogeneic stem 
cell transplantation for myeloid 
malignancies: A phase I trial. Biology 
of Blood and Marrow Transplantation. 
2016;22(7):1290-1298. DOI: 10.1016/j.
bbmt.2016.04.009
[78] Oevermann L, Michaelis SU, 
Mezger M, Lang P, Toporski J, Bertaina 
A, et al. KIR B haplotype donors 
confer a reduced risk for relapse 
after haploidentical transplantation 
in children with ALL. Blood. 
2014;124(17):2744-2747. DOI: 10.1182/
blood-2014-03-565069
[79] Brentjens RJ. Cellular therapies in 
acute lymphoblastic leukemia. Current 
Opinion in Molecular Therapeutics. 
2009;11(4):375-382
[80] Romanski A, Bug G, Becker S, 
Kampfmann M, Seifried E, Hoelzer 
D, et al. Mechanisms of resistance 
to natural killer cell-mediated 
Cancer Immunotherapy and Biological Cancer Treatments
18
cytotoxicity in acute lymphoblastic 
leukemia. Experimental Hematology. 
2005;33(3):344-352. DOI: 10.1016/j.
exphem.2004.11.006
[81] Miller JS, Cooley S, Parham P, Farag 
SS, Verneris MR, McQueen KL, et al. 
Missing KIR ligands are associated 
with less relapse and increased graft-
versus-host disease (GVHD) following 
unrelated donor allogeneic HCT. Blood. 
2007;109(11):5058-5061. DOI: 10.1182/
blood-2007-01-065383
[82] Willemze R, Rodrigues CA, Labopin 
M, Sanz G, Michel G, Socie G, et al. 
KIR-ligand incompatibility in the 
graft-versus-host direction improves 
outcomes after umbilical cord blood 
transplantation for acute leukemia. 
Leukemia. 2009;23(3):492-500. DOI: 
10.1038/leu.2008.365
[83] Cooley S, Weisdorf DJ, Guethlein 
LA, Klein JP, Wang T, Le CT, et al. 
Donor selection for natural killer cell 
receptor genes leads to superior survival 
after unrelated transplantation for 
acute myelogenous leukemia. Blood. 
2010;116(14):2411-2419. DOI: 10.1182/
blood-2010-05-283051
[84] Venstrom JM, Gooley TA, Spellman 
S, Pring J, Malkki M, Dupont B, 
et al. Donor activating KIR3DS1 is 
associated with decreased acute GVHD 
in unrelated allogeneic hematopoietic 
stem cell transplantation. Blood. 
2010;115(15):3162-3165. DOI: 10.1182/
blood-2009-08-236943
[85] Cooley S, Weisdorf DJ, Guethlein 
LA, Klein JP, Wang T, Marsh SG, et al. 
Donor killer cell Ig-like receptor B 
haplotypes, recipient HLA-C1, and 
HLA-C mismatch enhance the clinical 
benefit of unrelated transplantation for 
acute myelogenous leukemia. Journal of 
Immunology. 2014;192(10):4592-4600. 
DOI: 10.4049/jimmunol.1302517
